Avanir files Nuedexta in Europe
This article was originally published in Scrip
Executive Summary
Avanir Pharmaceuticals of the US has submitted an EU marketing authorisation application for Nuedexta (dextromethorphan HBr and quinidine sulfate) for the treatment of pseudobulbar affect (PBA).